CALIWAY BIOPHARMACEUTICALS CO., LTD.
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
Caliway’s pipeline includes: CBL‑514, an injectable drug targeting localized fat reduction, cellulite, and Dercum’s disease through adipocyte apoptosis; CBA‑539, a long‑acting injectable for hyperpigmentation and skin aging; and CBF‑520, a chemical entity
Founded Year
2012
Unified Business No.
53942917
Status
Active
Number of Employees
0
Total Paid-in
Capital
778,600,430 (NT$)
Location of Company
Taiwan
, New Taipei City
Exit Status
Emerging Stock Exchange(2025)、Listing(2024)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Caliway Biopharmaceuticals Co., Ltd. is a clinical‑stage biotech company headquartered in New Taipei City, Taiwan, dedicated to discovering novel small‑molecule therapeutics. The company focuses on aesthetic medicine and chronic inflammatory diseases, aiming to provide new, effective treatment options where current therapies are limited.
